Erleada Tablet, Film Coated
Product Images NDC 59676-604

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Erleada (NDC 59676-604). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Janssen Products, Lp, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Erleada 01)

Chemical structure of Apalutamide, the active ingredient in ERLEADA tablets. The diagram shows the molecular arrangement including nitrogen, sulfur, fluorine, oxygen atoms, and a cyclobutyl group within the chemical formula.*

FDA Label Image

Figure 1 (Erleada 02)

A Kaplan-Meier survival curve chart showing the percentage of subjects without an event over months from randomization comparing ERLEADA to placebo. The y-axis represents the percentage of subjects without event, and the x-axis shows months from randomization up to 57 months. The chart includes a legend for ERLEADA and placebo and a table of subjects at risk below the x-axis.*

FDA Label Image

Principal Display Panel (60 mg Tablet Bottle Label)

A Kaplan-Meier survival curve graph comparing the percentage of subjects without event over time for ERLEADA (apalutamide) versus placebo. The x-axis represents months from randomization up to 36 months, and the y-axis shows the percentage of subjects without event ranging from 0% to 100%. The graph includes two lines illustrating subject survival over time, with ERLEADA showing a higher percentage without event compared to placebo. Below the graph, a table lists the number of subjects at risk over time for each group.*

FDA Label Image

Erleada 04

This Kaplan-Meier survival curve chart shows metastasis-free survival probability (%) over months from randomization comparing ERLEADA (Apalutamide) to placebo. The chart includes survival probabilities for up to about 40 months with ERLEADA showing higher survival rates than placebo. A table below displays the number of subjects at risk at various time points for both groups.*

FDA Label Image

Erleada 05

A Kaplan-Meier survival curve chart comparing death-free survival probability (%) over months from randomization for ERLEADA (solid line) versus placebo (dashed line). The chart includes subjects at risk for both groups at various time points out to 76 months.*

FDA Label Image

Erleada 06

Erleada 60 mg film-coated tablets label showing apalutamide as the active ingredient. The label indicates 120 tablets per container and prescription-only status. It is manufactured by Janssen Orth LLC and labeled by Janssen Products, LP. Storage and dispensing instructions are also included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.